biotech · Pulmonary Disease, Chronic Obstructive · Symptomatic Neurogenic Orthostatic Hypertension · TBPH
Theravance Biopharma Ireland
Theravance Biopharma Ireland Umited
Theravance Biopharma Ireland is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker TBPH. Primary therapeutic focus areas include Pulmonary Disease, Chronic Obstructive, Sympt
901 Gateway Blvd., South San Francisco, CA 94080, US HQ
2014 Founded
177 Employees
Public company Type
TBPH · NYSE Ticker
Company details
- Status
- Public
- HQ
- 901 Gateway Blvd., South San Francisco, CA 94080, US
- Founded
- 2014
- Employees
- 177
- Programs
- 57
- Drugs
- 18
- Patents
- 635
Nezulcitinib (TD-0903) Dose A
Phase 1 · small molecule · Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
Nezulcitinib (TD-0903) Dose A for Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19) is a Phase 1 program (small_molecule) at Theravance Biopharma Ireland Umited with 1 ClinicalTrials.gov record(s).
Internal code 0196
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Theravance Biopharma Ireland Umited
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
- Status
- completed
- Trials
- 1